Found 91 clinical trials
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2
- 45 views
- 26 Jan, 2021
- 16 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate
- 23 views
- 25 Jan, 2021
- 8 locations
-
Accepting pediatric ages
-
Accepting Seniors
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
The Resistance and Immune Response to Palbociclib in Breast Cancer
Breast Cancer (BC) treated with Palbociclib in combination with endocrine therapies.
- 4 views
- 22 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy Concurrent Chemoradiation Therapy Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative HPV-Unrelated Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by
- 6 views
- 28 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Oncology
-
Currently Recruiting
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast cancer (BC) patients
- 2 views
- 25 Jan, 2021
- 5 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC
The goal of this research study is to determine if the investigators can predict which participants will respond to an aromatase inhibitor and palbociclib for metastatic breast cancer and which
- 12 views
- 24 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Locoregional Treatment and Palbociclib in de Novo Treatment Naive Stage IV ER+ HER2- Breast Cancer Patients
Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases. Despite a decrease in mortality in Europe and North America due to early detection and access to treatment, breast cancer remains the 2 …
- 0 views
- 25 Jan, 2021
- 34 locations
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Oncology
-
Currently Recruiting
A Study of the Use of Text Message Reminders to Take Palbociclib
The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these
- 8 views
- 27 Jan, 2021
- 7 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
HOPE: Olaparib Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated HR+ HER2-metastatic Breast Cancer
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast
- 0 views
- 04 Mar, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
. Patients will be randomized to receive either palbociclib + exemestane + OFS (Arm 1) or exemestane +OFS (Arm 2). Treatment will be continued until disease progression, unacceptable toxicities, or
- 0 views
- 23 Jan, 2021
- 1 location